
Virologic Response Associated With a Change in Protease Inhibitor Therapy
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
In the report by Guardiola and colleagues,1 a switch in protease inhibitor (PI) therapy for reasons other than therapeutic failure occurred in 74% of patients who were treated with PI-based regimens. The therapeutic strategy in these patients needs careful assessment before PI changes, since the patients may be put at greater risk for therapeutic failure after therapy change.
Figure 1 shows the virologic response in 14 patients who had a switch in PI after having achieved viral RNA suppression (viral RNA load <400 copies per milliliter) compared with 28 patients who continued to receive a successful regimen. Patients from 2 clinics were included in this retrospective chart review if they were treated with an indinavir sulfate regimen for at least 6 months and had 2 viral RNA measures below detection while receiving indinavir-combination therapy.2 From this group, patients were further identified for the switch group if their PI therapy had . . . [Full Text of this Article]
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age
Sanders et al.
ANN INTERN MED 2008;148:889-903.
ABSTRACT
| FULL TEXT
Nutritional Modulation of Blood Parameters in Type 2 Diabetes
Bell and Shabert
The Diabetes Educator 2001;27:368-375.
|